Bulk Pharmaceutical API Sources for TAVALISSE

Bulk Pharmaceutical API Sources for TAVALISSE

Vendor	Vendor Homepage	Vendor Sku	API Url
BioChemPartner		BCPP000226
BioChemPartner		BCP9000704
Molport		MolPort-016-633-314
Finetech Industry Limited		FT-0668866
Synblock Inc		PB25570
Molport		MolPort-021-804-956

Bulk Active Pharmaceutical Ingredient (API) Sources for TAVALISSE

Last updated: July 28, 2025

Introduction

TAVALISSE (fostamatinib disodium hexahydrate) is an oral spleen tyrosine kinase (SYK) inhibitor primarily approved for the treatment of chronic immune thrombocytopenia (ITP) in adults. As a complex molecular entity, the manufacturing and sourcing of its active pharmaceutical ingredient (API) involve high standards of quality, regulatory compliance, and supply chain integrity. Ensuring reliable bulk API sources is critical for pharmaceutical companies seeking to produce TAVALISSE at commercial scale.

This article provides an in-depth analysis of the current and potential API sourcing avenues for TAVALISSE, emphasizing key considerations such as manufacturing capacity, regulatory compliance, quality assurance, and strategic procurement.

---

Overview of TAVALISSE API Manufacturing

TAVALISSE’s API, fostamatinib disodium hexahydrate, is a phosphonate prodrug that inhibits SYK, interfering with immune cell signaling. Its synthesis involves multiple advanced chemical processes, including the production of the phosphonate moiety and subsequent formulation as the disodium salt hexahydrate. Given its sophisticated synthesis pathway, sourcing quality API hinges on specialized chemical manufacturing capabilities, rigorous quality standards, and reliable supplier relationships.

---

Key Characteristics of TAVALISSE API

• Chemical Name: Fostamatinib disodium hexahydrate
• Molecular Weight: Approx. 639.3 g/mol
• Formulation: Anhydrous or hydrate salts suitable for capsule or tablet manufacture
• Regulatory Status: Approved by agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other global regulatory bodies

The API’s unique chemical structure necessitates precise manufacturing controls, which often limits sourcing options to specialized chemical producers with proven expertise in phosphonate compounds and drug salts.

---

Global API Manufacturers for Fostamatinib Disodium Hexahydrate

1. Original Manufacturer and Licensed Suppliers

Rigel Pharmaceuticals devised the synthesis pathway for TAVALISSE, partnering initially with contract manufacturing organizations (CMOs) to produce the API at scale. As the original innovator, Rigel’s licensing agreements with production partners ensure high standards for quality and GMP (Good Manufacturing Practice) compliance.

2. Contract Manufacturing Organizations (CMOs)

Many CMOs globally hold the capability to manufacture complex APIs like fostamatinib disodium hexahydrate. Notable entities include:

• Patheon (Thermo Fisher Scientific): A prominent player with extensive experience in complex API manufacturing under GMP conditions.
• Samsung Biologics & Samsung Bioepis: Known for advanced chemical manufacturing capabilities, including phosphonate compounds.
• WuXi AppTec: A global CMO with extensive API manufacturing experience in complex pharmaceuticals, including kinase inhibitors.
• Lonza: Recognized for robust APIs manufacturing capabilities and compliance infrastructure.

3. Chinese API Manufacturers

China remains a significant source of pharmaceutical intermediates and APIs, including complex kinase inhibitors. Several Chinese API manufacturers have achieved GMP certification for fostamatinib or similar phosphonate molecules, driven by domestic demand and export opportunities:

• Hepalink: Known for phosphonate and organophosphorus chemistry, with GMP-certified API manufacturing facilities.
• BrightGene Bio-Medical Technology: Specializing in nucleotide and kinase inhibitor APIs, including kinase-targeting drugs.
• Aspiremeds and United Laboratories: Emerging API producers with capabilities in complex chemistries.

Note: Companies from China often offer cost advantages but require rigorous quality validation and regulatory due diligence.

4. Indian API Manufacturers

India’s API industry is extensively developed, with several firms producing complex molecules under stringent quality standards:

• Glenmark Pharmaceuticals: Has capabilities for kinase inhibitors and phosphonate compounds, with GMP certification.
• Aurobindo Pharma: Produces a wide range of complex APIs, with proven regulatory compliance.
• Sun Pharmaceutical Industries: An established player with large-scale API manufacturing infrastructure.

---

Criteria for Selecting API Suppliers

When evaluating bulk API sources for TAVALISSE, manufacturers must consider:

• GMP Certification and Regulatory Compliance: Ensures APIs meet international standards for safety, purity, and potency.
• Manufacturing Capacity: Sufficient scale to meet projected demand without supply disruptions.
• Quality Control & Consistency: Rigorous QC measures to maintain batch-to-batch uniformity; stability profiles.
• Supply Chain Transparency: Traceability of raw materials, adherence to ethical and legal sourcing practices.
• Intellectual Property (IP) Protections: Compliance with patent laws and licensing agreements.
• Cost and Lead Times: Competitive pricing balanced with reliable delivery schedules.

---

Regulatory and Supply Chain Considerations

Securing a dependable API supply chain involves comprehensive due diligence. Regulatory agencies scrutinize manufacturing facilities during approval processes, emphasizing compliance with cGMP standards (current Good Manufacturing Practice).

Manufacturers should foster collaborative relationships with API suppliers to mitigate risks related to geopolitical factors, supply disruptions, or quality lapses. Also, engaging multiple suppliers is prudent for risk diversification.

---

Future Outlook and Trends

As TAVALISSE expands globally, API sourcing strategies will evolve. Anticipated trends include:

• Increased Capacity Building by Existing Suppliers: Expansion of GMP-certified facilities to meet global demands.
• Emergence of New Suppliers in Asia: Driven by technological advancements and investment in phosphonate chemistry.
• Enhanced Supply Chain Transparency: Adoption of blockchain and digital tracking to ensure quality and compliance.
• Vertical Integration: Larger pharmaceutical companies may acquire or establish in-house manufacturing for strategic control.

---

Conclusion

The bulk API sourcing landscape for TAVALISSE encompasses a diverse array of global manufacturers, from original developers and licensed partners to Chinese and Indian producers. Given the molecule’s complexity, rigorous qualification of suppliers based on GMP compliance, capacity, and quality control measures is vital. Strategic sourcing, coupled with regulatory due diligence, will be critical for ensuring uninterrupted supply and consistent product quality for TAVALISSE.

---

Key Takeaways

• Reliable API sourcing for TAVALISSE is primarily driven by GMP-certified manufacturers with specialized phosphonate chemistry experience.
• Strategic relationships with CMOs, especially in regions like China and India, are increasingly common, but require thorough validation.
• Quality assurance, regulatory compliance, and supply chain transparency remain top priorities for pharmaceutical companies.
• Capacity expansion and technological innovation in API manufacturing are shaping future supply chain resilience.
• Due diligence and diversified supplier networks mitigate risks associated with supply disruptions and regulatory hurdles.

---

FAQs

1. What are the main criteria for selecting an API supplier for TAVALISSE?
GMP certification, manufacturing capacity, consistent quality, supply chain transparency, compliance with IP laws, and competitive pricing.

2. Are Chinese API manufacturers suitable for sourcing TAVALISSE API?
Yes, numerous Chinese manufacturers have GMP-certified facilities capable of producing complex kinase inhibitors like fostamatinib disodium hydrate, but require rigorous supplier validation to ensure quality.

3. How does regulatory compliance impact API sourcing decisions?
Regulatory compliance ensures APIs meet international standards, reducing the risk of approval delays and post-market issues; it’s critical to verify GMP status and audit reports.

4. What role do CMOs play in the API supply chain for TAVALISSE?
CMOs manufacture the API according to specified quality standards, offering scalability and flexibility; their reliability directly impacts supply chain stability.

5. What emerging trends could influence API sourcing for TAVALISSE?
Increased capacity, technological advances in phosphonate chemistry, digital transparency tools, and vertical integration are shaping the future of API procurement strategies.

---

Sources:

1. Rigel Pharmaceuticals. TAVALISSE (fostamatinib) drug information.
2. U.S. Food and Drug Administration. TAVALISSE approval documentation.
3. WHO Global Pharmaceutical Market Report.
4. Contract Manufacturing Organizations: Capabilities and Certifications.
5. Industry insights into phosphonate chemistry and kinase inhibitor APIs.